Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy

被引：142

作者：

Kasami, Masako ^{[1
]}

Uematsu, Takayoshi ^{[2
]}

Honda, Masatake ^{[1
]}

Yabuzaki, Tsugumi ^{[1
]}

Sanuki, Junichi ^{[3
]}

Uchida, Yoshihiro ^{[3
]}

Sugimura, Haruhiko ^{[4
]}

机构：

[1] Shizuoka Canc Ctr Hosp & Res Inst, Dept Pathol, Nagaizumi, Shizuoka 4118777, Japan

[2] Shizuoka Canc Ctr Hosp & Res Inst, Breast Imaging Sect, Shizuoka 4118777, Japan

[3] Shizuoka Canc Ctr Hosp & Res Inst, Dept Breast Surg, Shizuoka 4118777, Japan

[4] Hamamatsu Med Univ, Sch Med, Dept Pathol, Hamamatsu, Shizuoka 4313192, Japan

来源：

BREAST | 2008年 / 17卷 / 05期

关键词：

Estrogen receptor; Progesterone receptor; Her-2; Immunohistochemistry; Fluorescence in situ hybridization; Neoadjuvant chemotherapy;

D O I：

10.1016/j.breast.2008.04.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Neoadjuvant chemotherapy (NAC) is now a relatively standard treatment for breast carcinoma. However, some tumors are known to develop resistance to chemotherapies. We investigated whether the status of estrogen receptor (ER), progesterone receptor (PR) and Her-2 expressions in breast cancer cases prior to NAC could be changed after NAC. We used immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods. No differences were found in ER or Her-2 Status, but a significant difference was found in PR status. Changes in Her-2 status were suspected in four specimens after NAC (3+ to 1+ for 3 patients, and 1+ to 3+ for one patient) according to the IHC results. However, in all four of these cases, FISH of the resections showed no change. When IHC indicates a change in Her-2 expression after NAC, FISH is recommended. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：523 / 527

页数：5

共 24 条

[1]

How do we measure a residual size in Histopthology (the gold standard) after neoadjuvant chemotherapy? [J].

Apple, S. K. ;

Suthar, F. .

BREAST, 2006, 15 (03) :370-376

[2]

HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer [J].

Arens, N ;

Bleyl, U ;

Hildenbrand, R .

VIRCHOWS ARCHIV, 2005, 446 (05) :489-496

[3]

Bottini A, 1996, ANTICANCER RES, V16, P3105

[4]

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer [J].

Burcombe, RJ ;

Makris, A ;

Richman, PI ;

Daley, FM ;

Noble, S ;

Pittam, M ;

Wright, D ;

Allen, SA ;

Dove, J ;

Wilson, GD .

BRITISH JOURNAL OF CANCER, 2005, 92 (01) :147-155

[5]

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome [J].

Faneyte, IF ;

Schrama, JG ;

Peterse, JL ;

Remijnse, PL ;

Rodenhuis, S ;

van der Vijver, MJ .

BRITISH JOURNAL OF CANCER, 2003, 88 (03) :406-412

[6]

Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer [J].

Fehm, Tanja ;

Becker, Sven ;

Becker-Pergola, Graziella ;

Sotlar, Karl ;

Gebauer, Gerhard ;

Duerr-Stoerzer, Silke ;

Neubauer, Hans ;

Wallwiener, Diethelm ;

Solomayer, Erich-Franz .

BREAST CANCER RESEARCH, 2006, 8 (05)

[7]

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J].

Fisher, B ;

Brown, A ;

Mamounas, E ;

Wieand, S ;

Robidoux, A ;

Margolese, RG ;

Cruz, AB ;

Fisher, ER ;

Wickerham, DL ;

Wolmark, N ;

DeCillis, A ;

Hoehn, JL ;

Lees, AW ;

Dimitrov, NV .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) :2483-2493

[8]

Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer [J].

Hannemann, J ;

Oosterkamp, HM ;

Bosch, CAJ ;

Velds, A ;

Wessels, LFA ;

Loo, C ;

Rutgers, EJ ;

Rodenhuis, S ;

van de Vijver, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3331-3342

[9]

American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer [J].

Harris, Lyndsay ;

Fritsche, Herbert ;

Mennel, Robert ;

Norton, Larry ;

Ravdin, Peter ;

Taube, Sheila ;

Somerfield, Mark R. ;

Hayes, Daniel F. ;

Bast, Robert C., Jr. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5287-5312

[10]

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J].

Harvey, JM ;

Clark, GM ;

Osborne, CK ;

Allred, DC .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1474-1481

← 1 2 3 →